Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants

NCT03173573 is registered in ClinicalTrials.gov with Flatley Discovery Lab LLC as lead sponsor.

NCT NCT03173573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03173573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants
Lead sponsor
Flatley Discovery Lab LLC
Phase
Phase 1
Overall status
Completed
Start date
June 27, 2017
Completion date
May 31, 2018
Enrollment
109 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis